Last month (May 2025), Novo announced that the US Food and Drug Administration (FDA) accepted its new drug application (NDA) submission for an investigational once-daily oral formulation of Wegovy (semaglutide) for chronic weight management in adults living with obesity or overweight with one or more comorbid conditions and to reduce the risk of major adverse cardiovascular events in adults with overweight or obesity and established cardiovascular disease
doi: 10.1038/s41598-021-89834-9 306 ScherbakovNSzklarskiMHartwigJSotznyFLorenzSMeyerAet al
Graham GJ, Handel TM, Proudfoot A
This guide covers: How GLP-1 medications work and why their effects extend beyond glucose Blood sugar control: what results to expect Weight loss: magnitude and timeline Cardiovascular benefits: the evidence and what it means Kidney and liver protection Comparing different GLP-1 medications (semaglutide, tirzepatide, liraglutide, dulaglutide) How GLP-1s fit with other diabetes treatments Who benefits most from these medications Practical considerations for access and cost Key Takeaways GLP-1 medications produce comprehensive metabolic improvement , addressing blood sugar, weight, cardiovascular risk, and organ health simultaneously HbA1c reductions average 1.0-2.0 percentage points , with many patients achieving target levels under 7% Weight loss averages 10-15% with semaglutide , substantially more than older diabetes medications Cardiovascular event reduction of 20% has been demonstrated in high-risk patients, making GLP-1s the preferred choice for patients with heart disease Kidney protection extends beyond what glucose control alone would provide Tirzepatide (dual GLP-1/GIP agonist) produces greater improvements than single-mechanism GLP-1 agonists These medications can reduce or eliminate the need for other diabetes drugs , including insulin in many cases Side effects are primarily gastrointestinal and usually improve with time and proper titration Cost remains a barrier , though compounded options and manufacturer programs improve access GLP-1 medications are now recommended as first-line treatment for many Type 2 diabetes patients, particularly those with cardiovascular disease or obesity Understanding GLP-1 Medications Before exploring their benefits, understanding how these medications work explains why they affect so many aspects of metabolic health
153 MCP-1 belongs to the CC chemokine family and functions as a chemoattractant for mononuclear phagocytes, T lymphocytes, B cells, and natural killer cells
N.SalinasG
